MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach | MicrobiomeTrials← Back to trialsNCT06050707
MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2023-09-29Est. Completion: 2028-09-01
Enrollment target: 80 participants Locations- Allegheny Health Network, Pittsburgh, Pennsylvania, United States
- Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States
- Austin Health, Heidelberg, Victoria, Australia
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada
- CHUM - Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
Other microbiome trials you might be interested in
Bladder CancerSquamous Cell Carcinoma of the LungEsophageal Squamous Cell CarcinomaTongue Squamous Cell CarcinomaCutaneous Squamous Cell CancerPenile Squamous Cell CarcinomaAnal Squamous Cell CarcinomaVulvar Squamous Cell CarcinomaCervical Squamous Cell CarcinomaVaginal Squamous Cell CarcinomaUrethral Squamous Cell Carcinoma
The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial…
Los Angeles, United StatesEst. completion Jan 29, 2029
HIVGonorrheaChlamydiaAnal Cancer Squamous Cell
This project will test ways to reduce stigma in healthcare settings so that more providers offer, and more patients rece…
Biloxi, United StatesEst. completion Jul 31, 2030